ACURA PHARMACEUTICALS, INC 8-K

What Happened

• Acura Pharmaceuticals filed an 8-K (Mar 10, 2026) disclosing that it received three loans of $100,000 each from Abuse Deterrent Pharma, LLC on Feb 6, 2026, Feb 13, 2026 and Mar 9, 2026. These loans, together with prior advances and the $2,319,279 under the Nov. 10, 2022 Amended, Consolidated and Restated Secured Promissory Note, bring the note principal to $9,894,279 with accrued interest of approximately $1,040,000 as of Feb. 28, 2026. The Note bears interest at 5.25% (default interest 7.5% on overdue amounts). The company says the AD Pharma funding is for day‑to‑day operations and warns that, without additional financing by the end of March 2026, it will need to scale back operations, furlough or lay off employees, or seek bankruptcy protection.

Key Details

• Lender: Abuse Deterrent Pharma, LLC; new loans: $100,000 each on Feb 6, Feb 13 and Mar 9, 2026.
• Secured note principal: $9,894,279; accrued interest ≈ $1,040,000 (as of Feb 28, 2026).
• Interest rate: 5.25% per annum; overdue/default interest: 7.5% per annum from date of non‑payment.
• Company warning: insufficient additional financing by end of March 2026 may force operational scale‑backs, layoffs, or bankruptcy; company also references June 30, 2026 deadlines tied to FDA acceptance and payoff obligations under its agreement with AD Pharma.

Why It Matters

• This filing signals constrained liquidity: secured debt and accrued interest are material and growing, and the company explicitly states it needs more funding by the end of March 2026 to avoid severe operational cuts or bankruptcy.
• For investors, the risks are concrete and time‑sensitive: increased leverage, potential for default or accelerated repayment, and possible operational disruptions that could materially impact future value and equityholder recoveries.
• The filing also links financing to regulatory milestones (e.g., FDA/NDA timing and a June 30, 2026 target), meaning funding, regulatory progress, and repayment terms are interdependent and material to the company’s outlook.